基于脂质的纳米载体的最新进展,用于先进的皮肤癌治疗
Mohd Shoab Ali1, Mohammad Ali Abdullah Almoyad2, Shadma Wahab3
1Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062 India.
International journal of pharmaceutics
|January 11, 2025
概括
基于脂质的纳米颗粒为治疗皮肤癌提供了一个有希望的解决方案,增强药物输送和透. 这些纳米载体有效治疗皮肤瘤并克服抵抗力,显示了未来皮肤癌治疗的潜力.
科学领域:
- 纳米技术纳米技术
- 皮肤病学 皮肤病学
- 在瘤学瘤学.
背景情况:
- 皮肤癌是全球普遍存在的健康问题,通常对传统治疗有抗性.
- 有效的皮肤癌治疗需要加强药物透深入皮肤层.
- 传统配方难以有效地将治疗剂送到瘤部位.
研究的目的:
- 审查目前关于皮肤癌治疗的基于脂质的纳米载体的研究.
- 突出纳米载体在改善皮肤恶性瘤药物输送和疗效方面的潜力.
- 讨论脂质纳米载体在克服治疗耐药性和增强皮肤透方面的优势.
主要方法:
- 对利用基于脂质的纳米载体用于皮肤癌治疗的研究进行文献综述.
- 对纳米载体属性的分析,包括尺寸,生物相容性和生物降解性.
- 检查增强药物溶解性,稳定性和皮肤透性的机制.
主要成果:
- 基于脂质的纳米载体 (<100 nm) 证明了药物的有效传递到皮肤瘤.
- 这些纳米载体增加了疏水化学疗法的可溶性和稳定性,克服了耐药性.
- 脂质纳米载体通过与脂质双层相互作用,促进局部应用并增强皮肤透.
结论:
- 基于脂质的纳米载体是治疗皮肤癌的有效工具.
- 它们的生物相容性和生物降解性使得它们适用于局部药物输送.
- 进一步探索和建立这些纳米载体可以对抗日益增加的皮肤癌发病率.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Skin Cancer
3.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.1K


